NCT02838173

Brief Summary

This study compare the "Serratus block plane" (SPB) and the local infiltration of the tissue in the prevention of acute and chronic pain after breast cancer surgery.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2016

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2016

Completed
1 day until next milestone

Study Start

First participant enrolled

July 1, 2016

Completed
19 days until next milestone

First Posted

Study publicly available on registry

July 20, 2016

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

July 20, 2016

Status Verified

June 1, 2016

Enrollment Period

1.4 years

First QC Date

June 30, 2016

Last Update Submit

July 19, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • postoperative chronic pain assessed using the DN4 questionnaire

    DN4 questionnaire

    3 months postoperative

Secondary Outcomes (2)

  • postoperative acute pain

    day 1, day 2, day 3 postoperative

  • morphine consumption

    day 1, day 2, day 3 postoperative

Other Outcomes (2)

  • length of stay in the Postoperative Acute Care Unit

    through study completion

  • length of stay in hospital

    through study completion

Study Arms (2)

SPB

EXPERIMENTAL

Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision

Procedure: serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)Procedure: tissue infiltration : placebo

tissue infiltration

ACTIVE COMPARATOR

tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision

Procedure: tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)Procedure: serratus plane bloc : placebo

Interventions

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women scheduled for elective breast neoplasm surgery
  • Of ASA classification 1, 2 or 3
  • Patients who provide written informed consent

You may not qualify if:

  • Minor patients
  • Patients refusing to sign the consent
  • Patients included in another protocol within 3 months
  • Pregnant or lactating patients
  • Patients with history of allergy to local anesthetics (Ropivacaine)
  • Patients with contraindication to regional anesthesia (coagulopathy, local infection ...)
  • Patients with history of prior breast surgery (excluding diagnostic biopsy)
  • Patients with history of chronic pain
  • Patients with a history of psychiatric disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013 Nov;68(11):1107-13. doi: 10.1111/anae.12344. Epub 2013 Aug 7.

    PMID: 23923989BACKGROUND
  • Andreae MH, Andreae DA. Regional anaesthesia to prevent chronic pain after surgery: a Cochrane systematic review and meta-analysis. Br J Anaesth. 2013 Nov;111(5):711-20. doi: 10.1093/bja/aet213. Epub 2013 Jun 28.

    PMID: 23811426BACKGROUND

MeSH Terms

Conditions

Postoperative ComplicationsChronic Pain

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Luc Van Obbergh, MD PhD

    Erasme University Hospital

    STUDY DIRECTOR

Central Study Contacts

Céline Boudart, MD

CONTACT

Wendy Villareal Fernandez, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

June 30, 2016

First Posted

July 20, 2016

Study Start

July 1, 2016

Primary Completion

December 1, 2017

Study Completion

March 1, 2018

Last Updated

July 20, 2016

Record last verified: 2016-06